Abstract: Objective: To evaluate efficacy and safety of dupilumab in the treatment of moderate and severe atopic dermatitis (AD). Methods: A retrospective study was conducted among 18 patients with moderate to severe AD treated by dupilumab from June 19, 2020 to November 19, 2021. The clinical and laboratory data were analyzed and the efficacy and safety were accessed. The severity of skin lesions and itching were evaluated by Eczema Area and Severity Index (EASI) and Peak Itching Digital Evaluation Scale (NRS). Results: At week 16, the patients' EASI (4.78±4.80) and NRS (2.39±2.43) were significantly decreased than those before treatment (17.91±10.82, 6.78±2.05) (Ps<0.05). The qualified rates of EASI 50, EASI 75 and EASI 90 were 50%, 16.7% and 5.6% respectively after treated for 4 weeks, and 94%, 55.6% and 27.8% for 16 weeks. Seven patients (38.9%) had mild adverse reactions, and the most common adverse reaction was scaling. Conclusion: Dupilumab is effective and safe in the treatment of moderate and severe AD.

Key words: atopic dermatitis, Dupilumab, Interleukin-4, safety